
    
      Study Design - the assessment of patients with multiple tumour sites with metastatic thyroid
      cancer to correlate the administered activity to absorbed dose. Patients will receive the
      standard therapy dose of 5.5 GBq as per the hospital policy and there will be no change for
      the protocol purpose.
    
  